

CIBMTR is a collaborative resource of data and experts supporting research in cellular therapies to improve patient outcomes.

CIBMTR strategy is organized into 5 pillars:



ASH ABSTRACTS: Saturday, December 7, 2024

| Title | Status | Time/Session | Presenter |
|--|--------|--|----------------------|
| 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702 | Oral | 9:30 AM - 11:00 AM Presentation: 10:00 AM Session: 653 | Rahul Banerjee |
| Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL) Clinically Relevant Abstract | Oral | 9:30 AM - 11:00 AM Presentation: 10:30 AM Session: 628 | Alaa Ali |
| Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207 | Poster | 5:30 PM - 7:30 PM Session: 721 | Akshay Sharma |
| Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p) | Poster | 5:30 PM - 7:30 PM Session: 732 | Farrukh Awan |
| Identifying Disparities in Autologous Hematopoietic Cell Transplantation (autoHCT) Utilization for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in California | Poster | 5:30 PM - 7:30 PM Session: 906 | Naseem Esteghamat |
| Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis | Poster | 5:30 PM - 7:30 PM Session: 908 | Hemalatha Rangarajan |

ASH ABSTRACTS: Sunday, December 8, 2024

| Title | Status | Time/Session | Presenter |
|---|--------|--|----------------------|
| Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry | Oral | 9:30 AM - 11:00 AM Presentation: 9:45 AM Session: 626 | Maria Bobillo |
| Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry | Oral | 9:30 AM - 11:00 AM Presentation: 10:15 AM Session: 626 | Sairah Ahmed |
| Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) | Oral | 9:30 AM - 11:00 AM Presentation: 10:15 AM Session: 906 | Dasom (Caroline) Lee |
| Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report | Oral | 9:30 AM - 11:00 AM Presentation: 10:30 AM Session: 906 | Jiasheng Wang |

continued on next page ...

... continued from previous page

| Title | Status | Time | Presenter |
|--|--------|--|------------------------|
| Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) | Oral | 12:00 PM - 1:30 PM Presentation: 12:30 PM Session: 906 | Christopher Strouse |
| The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704 | Oral | 4:30 PM - 6:00 PM Presentation: 4:30 PM Session: 721 | Mohamed Sorror |
| Immunoepitidome Divergence between Mismatched HLA Haplotypes and Survival after Haploidentical HCT: A Retrospective Study from the CIBMTR | Oral | 4:30 PM - 6:00 PM Presentation: 4:45 PM Session: 732 | Katharina Fleischhauer |
| Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702 | Oral | 4:30 PM - 6:00 PM Presentation: 5:30 PM Session: 732 | Stephanie Lee |
| Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia | Poster | 6:00 PM - 8:00 PM Session: 619 | Laura Dillon |
| Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/ Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment | Poster | 6:00 PM - 8:00 PM Session: 651 | Dimitra Karagkouni |
| OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | Poster | 6:00 PM - 8:00 PM Session: 721 | Jeffery Auletta |
| Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial | Poster | 6:00 PM - 8:00 PM Session: 903 | Jeffery Auletta |
| Comparing Access to Allogeneic Hematopoietic Cell Transplant across the United States: Physician Density, Minority Health Social Vulnerability Index, Transplant Unmet Need and Utilization | Poster | 6:00 PM - 8:00 PM Session: 903 | Samantha Watters |

ASH ABSTRACTS: Monday, December 9, 2024

| Title | Status | Time | Presenter |
|---|--------|--|-------------------|
| Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT) | Oral | 2:45 PM - 4:15 PM Presentation: 4:00 PM Session: 723 | Angel Earle |
| Computational Structural Genomics Meets Cryo-EM for the Analyses of Mitochondria-Encoded Enzyme Complexes: A Transformational Approach for Deep Variant Phenotyping in Myelodysplastic Neoplasms | Oral | 4:30 PM - 6:00 PM Presentation: 4:45 PM Session: 893 | Jing Dong |
| Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis | Oral | 4:30 PM - 6:00 PM Presentation: 5:15 PM Session: 722 | Sameem Abedin |
| Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry | Poster | 6:00 PM - 8:00 PM Session: 623 | Daniel Landsburg |
| Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis | Poster | 6:00 PM - 8:00 PM Session: 722 | Robert Soiffer |
| To Treat or Not to Treat: Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant | Poster | 6:00 PM - 8:00 PM Session: 903 | Jaime Preussler |
| Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry | Poster | 6:00 PM - 8:00 PM Session: 906 | Kitsada Wudhikarn |